Clinic Roundup

• AVI BioPharma Inc., of Bothell, Wash., said it received approval from the FDA to proceed with a single oligomer, AVI-7288, in studies in both humans and nonhuman primates to support the safety and efficacy of post-exposure prophylaxis against Marburg virus infection. AVI-7288 is one of the two components that make up AVI-6003. AVI is conducting the work under a Department of Defense contract.